APA (7th ed.) Citation

Peñalver, F., Márquez, J., Durán, S., Giraldo, P., Martín, A., Montalbán, C., . . . Caballero, M. (2019). Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. Cancer Medicine, 8(16), 6955. https://doi.org/10.1002/cam4.2555

Chicago Style (17th ed.) Citation

Peñalver, Francisco‐Javier, et al. "Response‐adapted Treatment with Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients with Relapsed or Refractory Follicular Lymphoma After First‐line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial." Cancer Medicine 8, no. 16 (2019): 6955. https://doi.org/10.1002/cam4.2555.

MLA (9th ed.) Citation

Peñalver, Francisco‐Javier, et al. "Response‐adapted Treatment with Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients with Relapsed or Refractory Follicular Lymphoma After First‐line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial." Cancer Medicine, vol. 8, no. 16, 2019, p. 6955, https://doi.org/10.1002/cam4.2555.